Pure Global
NCT01585389

Studying Gene Expression and Location in Samples From Patients With Brain Tumors

Expression and Subcellular Localization of NEIL3 in Tumors
Children's Oncology Group·ClinicalTrials.gov·geneticCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Brain and Central Nervous System Tumors
Drug/Device/Intervention
gene expression analysis
Study type
Observational
Intervention type
genetic
Sponsor & location
Primary sponsor
Children's Oncology Group
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2012
End date
N/A
Enrollment
10 participants
Primary outcome

Correlation of NEIL3 expression and/or nuclear localization with tumor type or grade with respect to degree of differentiation

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may
 help doctors identify and learn more about biomarkers related to brain tumors.
 
 PURPOSE: This research studies gene expression and location in samples from patients with
 brain tumors.

ICD-10 classifications
Malignant neoplasm: Overlapping lesion of brain and other parts of central nervous systemMalignant neoplasm: Central nervous system, unspecifiedBenign neoplasm of brain and other parts of central nervous systemMalignant neoplasm of brainSecondary malignant neoplasm of other and unspecified parts of nervous system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT01585389
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT01585389 through Pure Global AI's free database. This phase not specified trial is sponsored by Children's Oncology Group and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.